Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa

Background and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreove...

Descripción completa

Detalles Bibliográficos
Autores: Garbayo-Salmons, Patricia|||0000-0003-3325-6785, Vilarrasa-Rull, Eva|||0000-0001-6507-0534, Bassas-Vila, Julio|||0000-0003-2787-750X, Mora Fernández, Verónica|||0000-0003-0016-9781, Fuertes, Irene, Luque-Luna, Mar|||0000-0002-0981-9149, Fornons-Servent, Rosa, Martin-Ezquerra, Gemma|||0000-0002-5106-7526, Aguayo Ortiz, Rafael|||0000-0002-1690-1618, Ceravalls, Joan|||0000-0003-0720-9280, Mollet, Jordi, Gómez Tomás, Álvaro, Masferrer i Niubò, Emili|||0000-0002-0763-2815, Corral-Magaña, Oriol, Matas-Nadal, Clara|||0000-0001-9911-6924, del Estal, Jorge|||0000-0001-7299-2211, Fuertes Bailón, Dani, Calvet, Joan|||0000-0002-0888-5152, Romaní, Jorge|||0000-0002-6134-5155
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:321055
Acceso en línea:https://ddd.uab.cat/record/321055
https://dx.doi.org/urn:doi:10.1111/jdv.20044
Access Level:acceso abierto
Palabra clave:Adalimumab
Survival
Discontinuation
Hidradenitis suppurativa
Descripción
Sumario:Background and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. Methods: We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. Results: Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic-naïve and 24.63% had undergone surgical treatment. During follow-up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. Conclusions: ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.

Similares en LA Referencia